Category

Intern. Socie.of Pharma. and Out.. Resea.

Home > Abstracts-Congresses > Intern. Socie.of Pharma. and Out.. Resea. (Page 8)

De Andres F, Vivancos J, Barriga FJ, Díaz F, Izquierdo L, Ortega MA, Castillo L, Ximénez-Carrillo A, Gómez-Escalonilla CI, Torres C, de Salas-Cansado M, Casado MA, Soto J, Gil-Nuñez A

 

Healthcare resource utilization and costs of cardioembolic stroke in the region of Madrid, Spain: preliminary results of CODICE study
15th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012

POSTER

Sánchez-de la Rosa R, Sabater E, Casado MA

 

 

 

Cost analysis of glatiramer acetate versus fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
15th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012

POSTER

Betegon L, Guilloteau I, Martin P, Woolmore A, Oyagüez I

 

 

The relative value of dasatinib versus imatinib as first-line treatment for chronic myeloid leukemiay
15th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012

POSTER

Cobo M, De Castro J, Isla D, Lozano V, Oyagüez I, Castro-Gomez AJ

 

 

Cost-effectiveness of erlotinib as first-line maintenance therapy for advanced non-small-cell lung carcinoma in patients EGFR WT and stable disease after four cycles of chemotherapy
15th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012

POSTER

Martinez-Raga J, Casado MA, González Saiz F, Oñate J

 

 

Budgetary impact analysis of Buprenorphine/Naloxone (Suboxone®) in opioid maintenance treatment in Spain
14th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Madrid, Spain 5-8 nov 2011

POSTER

Sánchez-de la Rosa R, Sabater E, Casado MA, Arroyo R

 

 

Cost-effectiveness Analysis of Disease Modifiying Drugs (Interferons and Glatiramer Acetate) as first line treatments in Remitting-Relapsing Multiple Sclerosis patients
14th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Madrid, Spain 5-8 nov 2011

POSTER

Sánchez-de la Rosa R, Sabater E, Casado MA

 

 

 

Budget impact analysis of first-line treatment for relapsing-remitting multiple sclerosis in Spain
14th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Madrid, Spain 5-8 nov 2011

POSTER

Garcia-Jurado L , Morano R, Torné A, Malvar A, Bayas JM, Pérez-Escolano I, Casado MA

 

 

Cost-efectiveness analysis of cervical cancer vaccination strategies in Spain
14th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Madrid, Spain 5-8 nov 2011

POSTER 

Álvarez-Sabín J, Masjuan, J, Yébenes M, Mar J, Oliva J, González-Rojas N, Becerra V, Casado MA, CONOCES Study Investigators

 

 

Are hospital costs for stroke underestimated in Spain?
14th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Madrid, Spain 5-8 nov 2011

POSTER